羟氯喹与系统性红斑狼疮患者的心血管事件
该研究基于法国国家医疗数据库(SNDS,覆盖99%法国人口)2010至2020年的数据,采用巢式病例对照设计,纳入52883例SLE患者,其中1981例发生符合条件的心血管事件,匹配16892例对照。当前使用羟氯喹(90天内)与复合心血管事件风险降低相关(OR 0.63;95%CI 0.57-0.69),与心肌梗死(OR 0.72;95%CI 0.60-0.85)、卒中(OR 0.69;95%CI 0.60-0.81)及其他血栓栓塞事件(OR 0.58;95%CI 0.49-0.69)分别也呈负相关;而91-365天的既往使用与心血管结局无关联。作者认为这凸显了SLE患者持续羟氯喹治疗的价值。
要点
- 当前使用羟氯喹(90天内)与复合心血管事件风险降低相关:OR 0.63(95%CI 0.57-0.69),对照为365天内无羟氯喹暴露。
- 当前使用羟氯喹与心肌梗死风险降低相关:OR 0.72(95%CI 0.60-0.85)。
- 当前使用羟氯喹与卒中风险降低相关:OR 0.69(95%CI 0.60-0.81)。
- 当前使用羟氯喹与其他血栓栓塞事件风险降低相关:OR 0.58(95%CI 0.49-0.69)。
- 既往使用羟氯喹(91-365天)与心血管结局无关联,作者强调持续治疗的价值。
适用人群与场景
- 法国国家医疗数据库(SNDS)中记录的全部SLE患者队列,共52883例(平均[SD]年龄44.23[16.09]岁;45255例[86.6%]女性;平均[SD]随访9.01[2.51]年)。
- 病例组为研究期间发生心血管事件的SLE患者(1981例),对照组为未发生心血管事件者(匹配16892例)。
- 匹配因素包括年龄、性别、SLE发病至进入SNDS数据库的时间、索引日期、既往抗血栓和心血管药物使用、慢性肾脏病及住院情况。
研究设计与关键结果
- 研究设计:基于法国国家医疗数据库(SNDS,覆盖99%法国人口)的巢式病例对照研究,2010至2020年,分析期为2022年2月至2023年9月。
- 暴露定义:索引日期前365天内羟氯喹使用,分为当前使用(90天内)、既往使用(91-365天)或前365天内无暴露。
- 主要终点为复合心血管事件,次要终点包括心肌梗死、卒中和其他血栓栓塞事件,分别分析。
- 当前使用羟氯喹与复合心血管事件风险降低相关:OR 0.63(95%CI 0.57-0.69),对照为365天内无羟氯喹暴露。
- 当前使用羟氯喹与心肌梗死风险降低相关:OR 0.72(95%CI 0.60-0.85)。
- 当前使用羟氯喹与卒中风险降低相关:OR 0.69(95%CI 0.60-0.81)。
- 当前使用羟氯喹与其他血栓栓塞事件风险降低相关:OR 0.58(95%CI 0.49-0.69)。
- 既往使用羟氯喹(91-365天)与心血管结局无关联。
证据类型、等级与局限
- 证据类型:基于全国性数据库的巢式病例对照研究。
对床旁实践的改变
- 作者认为,当前使用羟氯喹与心血管事件风险降低相关而既往使用无关联,凸显了SLE患者持续羟氯喹治疗的价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Systemic lupus erythematosus (SLE) predisposes individuals to early cardiovascular (CV) events. While hydroxychloroquine is thought to mitigate CV risk factors, its protective role against CV events, particularly arterial ones, remains to be confirmed.
OBJECTIVE: To evaluate the association between hydroxychloroquine and the risk of myocardial infarction (MI), stroke, and other thromboembolic events (OTEs) in patients with SLE.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study using a nested case-control design was conducted within the National French Healthcare Database (SNDS), which represents 99% of the French population, from 2010 to 2020. Participants were the cohort of all patients with SLE recorded in the SNDS. Patients with SLE experiencing CV events during the study period were the case group; those without CV events were controls. The analysis period was from February 2022 to September 2023.
EXPOSURES: Hydroxychloroquine use within 365 days prior to the index date, defined as current (within 90 days), remote (91-365 days), or no exposure within the previous 365 days.
MAIN OUTCOMES AND MEASURES: Outcomes of interest were MI, stroke, and OTE, analyzed individually and as a composite outcome (primary analysis). Controls were matched to patients with CV events by age, sex, time since SLE onset and entry into the SNDS database, index date, prior antithrombotic and CV medication, chronic kidney disease, and hospitalization. Multivariable conditional logistic regression was performed using hydroxychloroquine exposure as the main independent variable.
RESULTS: The SLE cohort included 52 883 patients (mean [SD] age, 44.23 [16.09] years; 45 255 [86.6%] female; mean [SD] follow-up, 9.01 [2.51] years), including 1981 patients with eligible CV events and 16 892 matched control patients. There were 669 MI events, 916 stroke events, and 696 OTEs in the individual outcome studies. For current exposure to hydroxychloroquine, the adjusted odds were lower for composite CV events (odds ratio [OR], 0.63; 95% CI, 0.57-0.69) as well as for MI (OR, 0.72; 95% CI, 0.60-0.85), stroke (OR, 0.69; 95% CI, 0.60-0.81), and OTEs (OR, 0.58; 95% CI, 0.49-0.69) individually compared with no hydroxychloroquine exposure within 365 days.
CONCLUSIONS AND RELEVANCE: In this nationwide cohort study of patients with SLE, a protective association was found between the current use of hydroxychloroquine and the occurrence of CV events, but not between remote use of hydroxychloroquine and CV outcomes, highlighting the value of continuous hydroxychloroquine treatment in patients with SLE.
参考来源
- Grimaldi L, Duchemin T, Hamon Y, et al. Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus. JAMA Netw Open. 2024. PMID: 39212983. doi:10.1001/jamanetworkopen.2024.32190
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。